

Cancer Prevention and Control CIRB Meeting Agenda

September 26, 2024

I. Amendment

URCC-22053, High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients (Version Date 08/13/24)

II. Amendment Prior to Activation

UMI22-09-02, Phase 1 Trial of ONC201 for Chemoprevention of Colorectal Cancer (Version Date 07/26/24)

III. Amendment

A222101, An Early Phase and Phase II Clinical Trial to Evaluate Ganglioside-Monosialic Acid (GM1) for Preventing Paclitaxel-Associated Neuropathy (Version Date 08/20/24)

IV. Continuing Review

A171601, A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer (Version Date 09/05/24)



V. Continuing Review

A221805, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Version Date 01/11/24)

VI. Continuing Review

UAZ21-07-01, M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention (Version Date 12/18/23)